FDA Inspection
Kedrion Biopharma Inc.Kedrion Biopharma Inc. – FDA Inspection, Aug 29, 2018
Record Details
This FDA Inspection record concerns Kedrion Biopharma Inc., with an inspection on August 29, 2018, issued by the Center for Biologics Evaluation and Research, covering biologics.
- People
- Jacqueline M. Diaz Albertini (Company Rep)
- Susan M. Jackson (Issuing Officer)
- Vioela Respress (Issuing Officer)
View Company Profile
ID · 65d6df47-9734-470a-9896-5df11ddf3333
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1064655
- FDA center
- Biologics
- Project area
- Blood and Blood Products
- Outcome
- Form 483 issued
Other FDA inspections of Kedrion Biopharma Inc.
6| Date | Classification | Office | Project area |
|---|---|---|---|
| March 27, 2024 | VAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| June 25, 2021 | VAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| November 16, 2018 | Not classified | New York District Office | |
| September 29, 2014 | VAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| August 2, 2012 | VAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
Other documents for Kedrion Biopharma Inc.
- FDA Inspection 1231467 - 2024-03-27
- FDA Inspection 1148187 - 2021-06-25
- FDA Inspection 1079026 - 2018-11-16
- FDA Inspection 900509 - 2014-09-29
- FDA Inspection 801013 - 2012-08-02
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.